not affect the company’s ability to deliver on its strategic and financing priorities.

The shares will be held in treasury for future use in connection with Galderma's employee participation plans, business development opportunities and/or treasury management.







“This repurchase reflects our confidence in Galderma’s future growth. Through our unique integrated dermatology strategy, consistent execution and financial discipline, we continue to strengthen our category leadership. This underscores our ambition to build the undisputed dermatology powerhouse, delivering attractive shareholder value creation and continuing to invest for the future.”



FLEMMING ØRNSKOV, M.D., MPH

CHIEF EXECUTIVE OFFICER

GALDERMA







Following the closing of the ABO, the free float in Galderma’s shares is expected to increase from 65% to 80%.

About Gald
=*=*=*=*=*=
当前为第2/7页
下一页-上一页-
=*=*=*=*=*=
返回新闻列表
返回网站首页